title: Facilitated ethanol metabolism promotes cardiomyocyte contractile dysfunction through autophagy in murine hearts.
abstract: Chronic drinking leads to myocardial contractile dysfunction where ethanol metabolism plays an essential role. Acetaldehyde, the main ethanol metabolite, mediates alcohol-induced cell injury although the underlying mechanism is still elusive. This study was designed to examine the mechanism involved in accelerated ethanol metabolism-induced cardiac defect with a focus on autophagy. Wild-type FVB and cardiac-specific overexpression of alcohol dehydrogenase mice were placed on a 4% nutrition-balanced alcohol diet for 8 weeks. Myocardial histology, immunohistochemistry, autophagy markers and signal molecules were examined. Expression of micro RNA miR-30a, a potential target of Beclin 1, was evaluated by real-time PCR. Chronic alcohol intake led to cardiac acetaldehyde accumulation, hypertrophy and overt autophagosome accumulation (LC3-II and Atg7), the effect of which was accentuated by ADH. Signaling molecules governing autophagy initiation including class III PtdIns3K, phosphorylation of mTOR and p70S6K were enhanced and dampened, respectively, following alcohol intake. These alcohol-induced signaling responses were augmented by ADH. ADH accentuated or unmasked alcohol-induced downregulation of Bcl-2, Bcl-xL and MiR-30a. Interestingly, ADH aggravated alcohol-induced p62 accumulation. Autophagy inhibition using 3-MA abolished alcohol-induced cardiomyocyte contractile anomalies. Moreover, acetaldehyde led to cardiomyocyte contractile dysfunction and autophagy induction, which was ablated by 3-MA. Ethanol or acetaldehyde increased GFP-LC3 puncta in H9c2 cells, the effect of which was ablated by 3-MA but unaffected by lysosomal inhibition using bafilomycin A(1), E64D and pepstatin A. In summary, these data suggested that facilitated acetaldehyde production via ADH following alcohol intake triggered cardiac autophagosome formation along with impaired lysosomal degradation, en route to myocardial defect.
authors.affiliation: Center for Cardiovascular Research and Alternative Medicine, University of Wyoming College of Health Sciences, Laramie, WY, USA.
authors.forename: Rui
authors.initials: R
authors.lastname: Guo
authors.forename: Nan
authors.initials: N
authors.lastname: Hu
authors.forename: Machender R
authors.initials: MR
authors.lastname: Kandadi
authors.forename: Jun
authors.initials: J
authors.lastname: Ren
mesh_terms: D000079:Acetaldehyde / Q000494:pharmacology; D000225:Adenine / Q000031:analogs & derivatives / Q000494:pharmacology; D000426:Alcohol Dehydrogenase / Q000378:metabolism; D000428:Alcohol Drinking / Q000378:metabolism; D000818:Animals; D001343:Autophagy / Q000187:drug effects; D015415:Biomarkers / Q000378:metabolism; D000431:Ethanol / Q000008:administration & dosage / Q000378:metabolism*; D005455:Fluorescent Antibody Technique; D006321:Heart / Q000187:drug effects / Q000503:physiopathology*; D008247:Lysosomes / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D035683:MicroRNAs / Q000378:metabolism; D008869:Microtubule-Associated Proteins / Q000378:metabolism; D009200:Myocardial Contraction / Q000187:drug effects; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D032383:Myocytes, Cardiac / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D051381:Rats; D015398:Signal Transduction / Q000187:drug effects; D019284:Thapsigargin / Q000494:pharmacology; D051020:bcl-X Protein / Q000378:metabolism
chemical_list: D015415:Biomarkers; C480860:Map1lc3b protein, mouse; D035683:MicroRNAs; D008869:Microtubule-Associated Proteins; C534715:Mirn30d microRNA, mouse; D051020:bcl-X Protein; D000431:Ethanol; C025946:3-methyladenine; D019284:Thapsigargin; D000426:Alcohol Dehydrogenase; D000079:Acetaldehyde; D000225:Adenine